Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective

INTRODUCTION: The MONALEESA-7 trial compared ribociclib plus endocrine therapy (ET) with placebo as first-line treatment of advanced luminal/HER2-negative breast cancer (ABC) in premenopausal and perimenopausal women (age <50 years) and showed significant benefits to progression-free survival and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, Daniela Dornelles, Magliano, Carlos Alberto da Silva, Simon, Sergio D., Amorim, Gilberto, Reinert, Tomás, Landeiro, Luciana, Gagliato, Débora de Melo, Exman, Pedro, Argolo, Daniel, Guilgen, Gisah, Mano, Max, Testa, Laura, Liedke, Pedro, Barroso, Romualdo, Sasse, Mariana, Buehler, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634995/
https://www.ncbi.nlm.nih.gov/pubmed/36339925
http://dx.doi.org/10.1177/17588359221100865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634995/
https://www.ncbi.nlm.nih.gov/pubmed/36339925
http://dx.doi.org/10.1177/17588359221100865

Ejemplares similares